Biocon gets EIR from USFDA for Andhra Pradesh facility

02 Sep 2024 Evaluate

Biocon has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA), for its greenfield API facility (Site 6), located at Visakhapatnam, Andhra Pradesh.

This is based on a pre-approval inspection conducted by the agency between June 10 and 14, 2024, and now allows the company to commence commercial supplies from this facility to the U.S. market.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

380.60 2.80 (0.74%)
16-Feb-2026 14:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1699.95
Dr. Reddys Lab 1269.00
Cipla 1352.20
Zydus Lifesciences 909.95
Lupin 2221.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×